SOPHiA GENETICS (NASDAQ:SOPH) CTO Abhimanyu Verma Sells 5,285 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.10, for a total value of $26,953.50. Following the completion of the sale, the chief technology officer owned 192,171 shares in the company, valued at approximately $980,072.10. This represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $5.44 on Wednesday. The firm has a market capitalization of $456.36 million, a price-to-earnings ratio of -10.46 and a beta of 0.96. The stock has a fifty day moving average of $5.13 and a 200 day moving average of $4.97. SOPHiA GENETICS SA has a 52 week low of $2.92 and a 52 week high of $6.30. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The company had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were mostly routine, pre-planned transactions tied to equity-award vesting and tax withholding, which suggests they may not signal a fundamental change in the business or management’s outlook.
• Neutral Sentiment: Multiple executives and directors, including Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, and others, reported sales in the same period, increasing investor focus on insider activity.
• Negative Sentiment: Even if planned, the cluster of insider share sales can create pressure on sentiment because it may be interpreted as reduced confidence or excess supply in the stock near term.

Analysts Set New Price Targets

Several research firms have weighed in on SOPH. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS currently has an average rating of “Hold” and a consensus target price of $7.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. Sei Investments Co. bought a new position in shares of SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. Principal Financial Group Inc. lifted its holdings in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter valued at approximately $2,157,000. Finally, First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter worth approximately $50,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.